YOLFTbeta
29

Hana Pharm Co Ltd

293480 · KO · Healthcare / Drug Manufacturers - Specialty & Generic

8,300.00KRW+110.00 (+1.34%)

Price History

Full chart

Market Stats

Previous Close8,190.00
Open8,190.00
Day Range8,190.00 – 8,350.00
52-Week Range8,100.00 – 11,804.05
Volume15.01K
Market Cap147.81B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield3.13%
Beta0.35
50-Day Avg8,487.80
200-Day Avg9,503.35

About

Hana Pharm Co., Ltd. develops and provides various pharmaceutical products in South Korea and internationally. It offers anesthetics, narcotic analgesics, antiemetics, muscle relaxants, cardiovascular and endocrine system, gastrointestinal system, respiratory system, antibiotics, dermatology, urinology, osteoporosis, and central nervous system products, as well as analgesics, antipyretics, and anti-inflammatory drugs. The company was founded in 1996 and is headquartered in Seoul, South Korea.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOTaehong Choi
  • Employees0
  • HeadquartersEK-Tower, Seoul, South Korea, 06162, Korea
  • Websitehttps://www.hanaph.co.kr

Leadership

  • Taehong ChoiPresident, CEO & Director
  • Hong-Joo YunDirector of Business Department, CFO & Director
  • Elia ChoDirector of Global Department & Director
  • Sang-yeop KimHead of New Product Research Lab

Financials

Income Statement

Currency: KRW2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue124.53B139.33B152.83B166.35B177.31B196.41B210.84B224.46B225.34B239.50B
Growth (%)-+11.88%+9.69%+8.84%+6.59%+10.77%+7.35%+6.46%+0.39%+6.29%
Cost of Revenue40.62B44.95B50.93B56.15B63.28B65.59B79.61B84.87B84.05B94.65B
Gross Profit83.91B94.38B101.91B110.20B114.02B130.82B131.24B139.58B141.29B144.86B
Gross Margin67.38%67.74%66.68%66.25%64.31%66.61%62.24%62.19%62.70%60.48%
Operating Expense60.24B62.45B68.34B76.63B82.35B94.81B100.07B112.55B116.14B119.04B
Operating Income23.67B31.93B33.56B33.57B31.68B36.01B31.17B27.03B25.15B25.82B
Operating Margin19.01%22.92%21.96%20.18%17.86%18.33%14.78%12.04%11.16%10.78%
EBITDA-35.53B36.19B39.12B33.54B41.65B37.80B34.68B32.87B36.97B
EBITDA Margin-25.50%23.68%23.52%18.92%21.21%17.93%15.45%14.59%15.44%
Net Income17.43B24.30B26.17B28.30B14.89B28.01B24.31B22.33B21.25B8.78B
Net Income Margin14.00%17.44%17.12%17.01%8.40%14.26%11.53%9.95%9.43%3.67%
R&D3.42B2.21B2.19B2.56B3.24B3.49B4.75B7.40B8.98B10.83B
R&D as % of Total Revenue2.75%1.59%1.43%1.54%1.83%1.78%2.25%3.30%3.99%4.52%
Interest Expense00298.99M55.49M52.00M45.19M585.67M897.41M--
Interest Expense % of Total Revenue0.00%0.00%0.20%0.03%0.03%0.02%0.28%0.40%--

Balance Sheet

Currency: KRW2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets114.59B141.55B242.38B263.03B276.58B303.50B345.96B348.39B382.01B418.14B
Total Liabilities59.11B60.25B36.99B42.70B44.20B51.60B77.57B70.40B72.83B104.73B
Total Equity55.48B80.94B205.39B220.33B232.38B251.90B268.40B277.98B309.18B313.41B
Cash1.39B12.94B16.99B14.98B20.55B6.62B12.55B1.42B8.52B9.84B
Net Debt-16.11B---1.78B17.90B22.01B18.61B46.42B

Cash Flow

Currency: KRW2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow12.46B25.38B27.59B31.72B15.58B25.66B30.88B18.40B25.30B9.18B
Investing Cash Flow-9.31B-12.82B--------
Financing Cash Flow-2.33B-1.01B--------
Capital Expenditure8.31B10.19B5.57B33.73B17.14B34.81B35.77B14.68B13.21B31.18B
Free Cash Flow-21.54B22.02B-2.01B-1.56B-9.16B-4.89B3.72B12.09B-22.01B
Dividends Paid1.02B1.02B3.01B4.51B7.24B8.02B8.82B8.82B8.82B8.82B
FCF to OCF-84.86%79.81%-6.35%-10.02%-35.69%-15.83%20.21%47.79%-239.81%
Dividend Paid to FCF-4.75%13.65%-223.72%-463.64%-87.62%-180.50%237.15%72.97%-40.09%

Earnings

Report DateNov 13, 2018Mar 21, 2019May 15, 2019Aug 13, 2019Nov 13, 2019Mar 19, 2020May 14, 2020Aug 14, 2020Nov 16, 2020Feb 8, 2021May 14, 2021Aug 16, 2021Nov 14, 2021Feb 13, 2022May 16, 2022Aug 16, 2022Nov 14, 2022Mar 22, 2023May 15, 2023Aug 11, 2023Nov 14, 2023Mar 15, 2024May 16, 2024Aug 14, 2024Nov 14, 2024Mar 14, 2025May 15, 2025Aug 12, 2025Nov 12, 2025Mar 12, 2026May 13, 2026Jun 30, 2026
EPS Estimate--------------------------------
EPS Actual542.00486.00381.52402.73435.04397.41321.82300.00480.00-241.56257.81532.00447.66410.10352.00339.00316.00397.63307.01445.73221.12317.09351.17290.84170.72415.64245.14319.52-246.17188.93564.99476.34
Surprise--------------------------------
TimingPre-marketAfter-hours-After-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market-

Key Statistics & Ratios

Market Cap147.81B
Enterprise Value197.45B
Trailing P/E0.00
Forward P/E0.00
Price / Sales1.06
Price / Book0.44
Revenue (TTM)139.33B
Gross Profit (TTM)94.00B
EBITDA35.33B
Profit Margin17.44%
Operating Margin22.83%
Return on Equity35.54%
Return on Assets15.52%
Shares Outstanding17.72M
Shares Float4.28M
Beta0.35
Dividend Yield3.13%
Dividend Rate260.00
Payout Ratio26.42%

Dividends

20251×
260.00Dec 29, 2025
20242×
510.00Dec 27, 2024510.00Jan 12, 2024
20221×
510.00Dec 28, 2022
20211×
510.00Dec 29, 2021
20201×
463.64Dec 29, 2020
20191×
418.18Dec 27, 2019
20181×
254.55Dec 27, 2018

Stock Splits

  • Apr 28, 20211.1:1